Filana Therapeutics (FLNA) Q3 2024 earnings summary

Executive summary

• Completion of last patient visit in the first phase III RETHINK-ALZ trial; top-line results from the 52-week study expected before year-end 2024, and from the 76-week study by mid-2025.

• Both phase III trials for simufilam, targeting mild-to-moderate Alzheimer's, are fully enrolled with approximately 1,900 patients; over 1,185 have completed the trials, and 88% of completers entered the open-label extension study.

• Optimism expressed for simufilam as a potential best-in-class Alzheimer's treatment, with results to be reported regardless of outcome.

• Significant leadership changes occurred, including the appointment of Richard J. Barry as President and CEO and the resignation of former CEO Remi Barbier and SVP Lindsay Burns, both entering consulting agreements.

• Company is expanding manufacturing, preparing commercial plans, and focusing on transforming Alzheimer's diagnosis and treatment, especially for primary care physicians.

Financial highlights

• Ended Q3 2024 with $149 million in cash and cash equivalents, sufficient to fund operations through both ongoing phase III trials and into 2026; no debt outstanding.

• Q3 2024 net loss was $27.9 million ($0.58 per share), compared to $25.7 million ($0.61 per share) in Q3 2023; nine-month net income was $3.3 million, driven by a $108.2 million non-cash gain from warrant liability changes.

• Net cash used in operations for the nine months ended September 30, 2024, was $55.7 million.

• R&D expenses for Q3 2024 were $17.7 million, down from $23.6 million year-over-year; G&A expenses rose to $12.9 million from $4.3 million, mainly due to legal and compensation costs.

• General and administrative expenses for the nine months ended September 30, 2024, rose sharply to $62.9 million, primarily due to the $40 million SEC settlement, higher legal costs, and increased stock-based compensation.

Outlook and guidance

• Top-line phase III results from the 52-week study expected before end of 2024, and from the 76-week study by mid-2025; biomarker data from approximately 100 patients to be reported simultaneously.

• Year-end 2024 cash projected between $117–$127 million, consistent with prior guidance.

• Net cash use in operations for H2 2024 expected to be $40–$50 million, in line with prior guidance; $40 million SEC settlement to be paid, already excluded from cash and equivalents.

• If successful, simufilam could reach the U.S. market by late summer or early fall 2026.

• R&D expenses are expected to decrease as phase III enrollment is complete, but G&A expenses will remain elevated due to ongoing legal matters and higher stock-based compensation.